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ÖZET
Asetilkolin esteraz inhibitörü olan hidrazid hidrazonlar 
üzerinde çalışmalar
Amaç: On beş adet hidrazit-hidrazon türevi sentezlenmiş ve asetilko-
linesteraz enzimini (AChE) inhibe etme yetenekleri Ellman’ın modifiye 
spektrofotometrik yöntemi ile değerlendirilmiştir. 
Yöntem: Anti-asetilkolinesteraz aktivite tayini Ellman’ın modifiye edilmiş 
spektrofotometrik yöntemi kullanılarak yapılmıştır. Bu spektrofotometrik 
yöntem bir kromojenik reaktif olan 5,5-ditiyo-bis-(2-nitrobenzoik asit) ile 
salınan tiyokolinin renkli bir ürün vermesi esasına dayanır. 
Bulgular: Test edilen bileşikler arasında, 4-fluorobenzoik asit [(4-metok-
sifenil) metilen] hidrazid(6) ve 2-[(fluorobenzoil) hidrazono]-1,3-dihidro-
indol-3-on (15), referans ilaç donezepil (IC50=0.054±0.002μM) ile kıyaslan-
dığında kayda değer anti-AChE aktivite göstermiştir. 
Sonuç: Anti- AChE aktivite sonuçları, p-metoksifenil sübstitüenti taşıyan 
bileşik 6 ve 1,3-dihidro-indol-3-on sübstitüenti taşıyan bileşik 15’in en 
aktif bileşikler olduğunu göstermiştir. Aktivite sonuçlarından, hidrazid-
hidrazon yapısı üzerinde hacimli grupların bulunmasının anti- AChE 
aktiviteye olumlu yönde katkıda bulunduğu görülmektedir. 
Anahtar sözcükler: Hidrazit, hidrazon, anti-asetilkolinesteraz aktivite
ABS TRACT
Studies on hydrazide–hydrazones derivatives as 
acetylcholinesterase inhibitors
Objective: Fifteen hidrazide-hydrazone derivatives were synthesized and 
evaluated for their ability to inhibit acetylcholinesterase (AChE) using a 
modification of Ellman’s spectrophotometric method. 
Methods: Anti-acetylcholinesterase activity was evaluated by 
using a modification of Ellman’sspectrophotometric method. The 
spectrophotometric method is based on the reaction of released 
thiocholine to give a coloured product with a chromogenic reagent 
5,5-dithio-bis-(2-nitrobenzoic acid).
Results: Among the tested compounds, 4-fluorobenzoic acid 
[(4-methoxyphenyl) methylene] hydrazide (6) and 2-[(fluorobenzoyl) 
hydrazono]-1,3-dihydro-indol-3-one (15), showed noteworthy 
anti-AChE activity when compared to standard drug donepezil 
(IC50=0.054±0.002μM). 
Conclusion: The anti-AChE activity screening indicated that among the 
tested compounds, 6 with p-methoxyphenyl substitution and 15 with1,3-
dihydro-indol-3-one substitution represent the most active compounds. 
Based on the activity results, it appears that bulky groups on the 
hydrazide-hydrazone moiety have made good contribution to the anti-
AChE activity. 
Key words: Hydrazide, hydrazone, anti-acetylcholinesterase activity
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 INTRODUCTION
 Alzheimer’s disease (AD) is a complex neurodegenerative 
brain disorder characterized by loss of memory, mood 
changes, and problems with communication and reasoning. 
AD is described by loss of cholinergic neurons and synaptic 
markers in cerebral cortex and in certain sub-cortical regions 
(1,2). Firstly, Alzheimer’s disease was reported in 1907 by the 
German neurologist Alois Alzheimer (3). Researchs in the 
last two decades have correlated Alzheimer’s disease with 
acetylcholine deficiency (4).Tacrine was the first of the AChE 
inhibitors approved for the AD treatment in 1993, but its use 
has been abandoned because of a high incidence of side 
effects including hepatotoxicity (4). 
 The use of enzymes-inhibition theory in the diagnosis of 
disease and synthesis of new drugs is one of the important 
benefits derived from the intensive research in medicine. 
The human body is composed of a wide variety of 
components, and has developed complex enzymatic 
inhibition mechanisms to alter the progress of many disease 
by drugs molecules (4,5). Since the cholinergic therapy may 
alter the symptoms and progress of AD by stopping any 
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decrease in acetylcholine level through inhibition of 
acetylcholineesterase enzyme, therefore a strategy for the 
treatment of AD is focused on acetylcholinesterase enzyme. 
Two ChEsare identif ied cl inical ly  in humans: 
acetylcholinesterase (AChE) and butyryl cholinesterase 
(BuChE). Both of them are present in cholinergic synapses, 
central nervous system (CNS), parasympathic synapses in 
the periphery, and in the neuro muscular junction. AChE is 
selective for ACh hydrolysis, while BuChE hydrolyses 
acetylcholine and other choline esters and as regarded its as 
a non-specific cholin esterase (5–11). Medications currently 
approved by regulatory agencies such as the U.S. Food and 
Drug Administration (FDA) and the European Medicines.
 Agents (EMA) to treat the cognitive manifestations of 
AD and to improve life quality of the patients are: donepezil, 
rivastigmine and galantamineas reversible AChE inhibitors, 
and memantine as a NMDA receptor antagonist (12). 
However these AChE inhibitors are known to have side 
effects such as hepatotoxicity, short half life and 
gastrointestinal tract excitement (13). Therefore the 
investigation on searching for new and better AChE 
inhibitors is still of great interest.
 Since that hydrazide-hydrazone moiety plays an 
important role for anticholinesterase activity (14-21), in the 
present study, prompted by these observations, we 
synthesized hydrazide-hydrazones derivatives as AChE 
inhibitors.
 MATERIALS AND METHODS
 Synthesis of Test Compounds
 General procedures for the preparation of target 
compounds 1-15 are described in Scheme 1. The 
4-fluorobenzoyl chloride was first reacted with phenol in 
alkaline medium, to give the corresponding ester 1 in very 
good yield (85%). This ester was then converted almost 
quantitatively to the hydrazide after treatment with 
hydrazine hydrate in dry methanol. The reaction of the 
hydrazide with aldehydes and ketones in ethanol afforded 
the corresponding substituted hydrazides 1-15 (Table 1). 
Physicochemical and spectroscopic characterization of all 
compounds have been previously described (22,23). 
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Scheme 1: Synthetic pathway for compounds 1-15
Reagents and conditions: (a) NaOH; (b) NH2NH2 , CH3OH; (c) RCHO, C2H5OH
Ai: Substituted phenyl / thiophenyl, furanyl, pyrolyl, isatine
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Table 1: The synthesized hydrazide-hydrazone derivatives
Comp. Ai Xi Comp. Ai Xi
1 A3 X3=H 9 A3
X2=OCH3; 
X3=OH
2 A3 X3=Br 10 A3
X2=O(C2H5); 
X3=OH
3 A3 X3=Cl 11 A1 -
4 A3 X3=F 12 A2 -
5 A3 X3= CH3 13 A4 -
6 A3 X3=OCH3 14 A5 -
7 A3 X3=N(CH3)2 15 A6 -
8 A3 X1=OH
SX1
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 Pharmacology
 AChE Inhibition
 All compounds were subjected to a slightly modified 
method of Ellman’s test (21) in order to evaluate their 
potency to inhibit the AChE. The spectrophotometric 
method is based on the reaction of released thiocholine to 
give a coloured product with a chromogenic reagent 
5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB). AChE, 
(E.C.3.1.1.7 from Electric Eel, 500 units), and Donepezil 
hydrochloride were purchased from Sigma–Aldrich 
(Steinheim, Germany). Potassium dihydrogenphosphate, 
DTNB, potassium hydroxide, sodium hydrogen carbonate, 
gelatine, acetylthiocholine iodide (ATC) were obtained 
from Fluka (Buchs, Switzerland). Spectrophotometric 
measurements were performed on a 1700 Shimadzu 
UV-1700 UV–Vis spectrophotometer. Cholinesterase 
activity of the compounds (1-15) was measured in 100 mM 
phosphate buffer (pH 8.0) at 25°C, using ATC as substrates, 
respectively. DTNB (10 mM) was used in order to observe 
absorbance changes at 412 nm. Donepezil hydrochloride 
was used as a positive control (Table 2) (25).
 Enzymatic assay
 Enzyme solutions were prepared in gelatin solution 
(1%), at a concentration of 2.5 units/mL. AChE and 
compound solution (50 µL) which is prepared in 2% DMSO 
at a concentration range of 10-1-10-6mM were added to 3.0 
mL phosphate buffer (pH 8±0.1) and incubated at 25°C for 
5 min. The reaction was started by adding DTNB (50 µL) and 
ATC (10 µL) to the enzyme-inhibitor mixture. The production 
of the yellow anion was recorded for 10 min at 412 nm. As a 
control, an identical solution of the enzyme without the 
inhibitor is processed following the same protocol. The 
blank reading contained 3.0 mL buffer, 50 μL 2% DMSO, 50 
μL DTNB and 10 μL substrate. All processes were assayed in 
triplicate. The inhibition rate (%) was calculated by the 
following equation:
 Inhibition %=(AC–AI)/AC x100
 Where AI is the absorbance in the presence of the 
inhibitor, AC is the absorbance of the control and AB is the 
absorbance of blank reading. Both of the values are 
corrected with blank-reading value. Data were expressed as 
Mean±SD.
 RESULTS AND DISCUSSION
 It was reported that hydrazone derivatives show anti-
acetylcholinesterase (AChE) activity (15,16,26,27). 
According to this information, the anti-AChE activity of the 
compounds (1-15) were determined by modified Ellman’s 
spectrophotometric method (Table 2). Among these (1-15) 
compounds, compound 15 with1,3-dihydro-indol-3-one 
substitution and compound 6 with p-methoxyphenyl 
substitution represent the most active compounds. Thus, 
inhibition percentages are 52,38 and 40,61% at 1 and 0.1 
mM concentrations for compound 15 and 46,08 and 42,85% 
at 1 and 0.1 mM concentrations for compound 6. The IC50 
values could not be well defined in all compounds. 
Compound 1 bearing phenyl moiety, compound 7 bearing 
4-(N,N-dimethyl- amino) phenyl moiety, and compound 12 
bearing 2-furanyl group exhibited anticholin-esterase 
activity with nearly 43% inhibition value. Compound 9, 11, 
13 and 14 showed moderate activity with the inhibition 
percentages about 41%. The other compounds 2, 3, 4, 5, 8 
and 10 showed relatively weak activity and the inhibition 
values were found to be less than 12,87%. Standard drug 
Donepezil was studied at lower concentrations for the 
purpose of finding IC50 value and it was determined as 
Table 2: AChE inbition (%) of the tested compounds and their IC50 
values
Comp.
AChE Inhibition (%)
1 mM 0.1 mM  IC50 (mM)
1 43,38±1,26 42,68±0,80 > 1
2 9,81±1,46 9,44±3,02 > 1
3 9,39±1,77 8,13±2,25 > 1
4 9,34±1,44 6,29±0,92 > 1
5 12,87±1,26 11,69±0,70 > 1
6 46,08±0,93 42,85±0,45 > 1
7 44,73±3,06 43,43±1,16 > 1
8 8,84±3,02 7,24±0,92 > 1
9 40,72±0,46 36,63±2,89 > 1
10 8,83±1,64 6,77±0,92 > 1
11 41,91±1,32 40,12±1,32 > 1
12 43,64±0,93 42,88±1,7 > 1
13 40,28±1,22 40,23±1,02 > 1
14 40,29±1,08 40,23±1,96 > 1
15 52,38±2,05 40,61±0,24 > 1
Donepezil 99,01±4,89 95,52±5,01 0,054±0,002(μM)
IC50: The half maximal inhibitory concentration
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0.054 µM. None of the compounds showed comparable 
activity with Donepezil and there were no significant anti-
AChE activity and this is contrary to expectations.
 CONCLUSION
 In conclusion, a series of hydrazide-hydrazone 
derivatives have been synthesized and screened for 
their anti-AChE activity. The anti-AChE activity screening 
indicated that among the tested compounds, 15 
with1,3-dihydro-indol-3-one substitution and 6 with 
p-methoxyphenyl substitution represent the most 
active compounds. Based on the activity results, it 
appears that bulky groups on the hydrazide-hydrazone 
moiety have made good contribution to the anti-AChE 
activity.
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